Patents by Inventor Tracy Lynn ARAKAKI

Tracy Lynn ARAKAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identifying potential inhibitors of APO TNF? trimers
    Patent number: 11674967
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 13, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Munro
  • ANTIBODY EPITOPE
    Publication number: 20220074947
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: May 19, 2021
    Publication date: March 10, 2022
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Tracy Lynn ARAKAKI, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Antibodies binding to trimeric TNF alpha epitopes
    Patent number: 11022614
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: June 1, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Tracy Lynn Arakaki, Daniel John Lightwood, Rebecca Jayne Munro
  • NOVEL TNFa STRUCTURE FOR USE IN THERAPY
    Publication number: 20210088530
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 25, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
    Patent number: 10775385
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Wootton
  • NOVEL TNFalpha STRUCTURE FOR USE IN THERAPY
    Publication number: 20180231562
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 16, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON
  • ANTIBODY EPITOPE
    Publication number: 20180172701
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: October 22, 2015
    Publication date: June 21, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Tracy Lynn ARAKAKI, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON